Searched for
PATENT INVALIDITY RULING
Apple defeats AliveCor bid to block US smartwatch imports in US appealThe US Court of Appeals for the Federal Circuit affirmed the invalidity of AliveCor heart-rate monitoring patents that the company had accu...- Micron, Dell, HP win appeal over conflict claims tied to US patent officialThe U.S. Court of Appeals for the Federal Circuit said the companies' adversary in the USPTO case, patent owner Unification Technologies, h...
- US Supreme Court won't review Apple's win against $503 million patent verdictApple and VirnetX were locked in a 14-year-long court battle over the latter's internet-security patents, a case which has seen several tri...
- US patent tribunal sides with Intel again in $2.2 billion VLSI caseThe Patent Trial and Appeal Board invalidated the computer chip-related patent after canceling another VLSI patent that accounted for the r...
- Joe Biden administration urges Supreme Court not to hear Apple-Caltech patent caseCalifornia-based Caltech sued Apple and Broadcom in Los Angeles federal court in 2016, alleging millions of iPhones, iPads, Apple Watches a...
- Google must face trial over Sonos patents, says California judgeThe case, set for trial May 8, is part of a contentious intellectual property dispute between the former business partners over their smart...
- Apple wins US appeal over patents in $502 million VirnetX verdictThe US Court of Appeals for the Federal Circuit affirmed a decision from the U.S. Patent and Trademark Office that invalidated the two pate...
- Biocon, Mylan win US court ruling in favour of insulin GlargineUS District Court of New Jersey found the device patent claims (US Patent No. 9526844) asserted by Sanofi against Biocon and Mylan’s insuli...
- US Court rules in favour of Mylan for Copaxone patents: NatcoIn December 2016, the US Patent and Trademark Office (PTO) had ruled in favour of Mylan and three patents related to Copaxone 40 mg/mL were...
- US Patents rejects Teva's plea on Copaxone; Natco shares upHyderabad-based Natco markets Copaxone (Glatiramer Acetate) -- used in the treatment of relapsing-remitting multiple sclerosis -- in the US...
- US agency makes initial ruling against Apple 'pinch-to-zoom' patentApple scored a sweeping legal victory over its South Korean competitor in August when a US jury found Samsung had copied critical features ...
- Sun wins patent case against Eli Lily over cancer drugSun Pharma today claimed victory over Eli Lily and Co in a patent litigation over Gemzar, used in cancer treatment, with a US federal court...
- Facebook beats back patent infringement claimFacebook Inc won a legal fight on Wednesday over claims its hugely popular social networking website infringed a patent owned by little-kno...
- Ranbaxy loses battle for Lipitor patent in CanadaIn a setback for Ranbaxy in its global battle over the patent of Lipitor, a Canadian federal court has ruled that the company’s generic dru...
- Ranbaxy wins Lipitor patent case in NorwayIn a boost to Ranbaxy in its ongoing litigation over anti-cholesterol drug Lipitor against Pfizer, a Norway court on Tuesday ruled that fou...
- Ranbaxy gets relief in Lipitor caseDomestic pharma firm Ranbaxy Laboratories has secured a favourable verdict from Canada's Federal Court in the 'Lipitor' case against global...
- US Court denies Ranbaxy's petition on Lipitor patentIn the ongoing patent battle over atorvastatin, Pfizer Inc on Monday claimed that the US Federal Court has denied Ranbaxy's petition for re...
- US denies to rehear Ranbaxy's Lipitor caseIn the ongoing patent battle over atorvastatin, Pfizer Inc on Tuesday claimed that the US Federal Court has denied Ranbaxy's petition for r...
- Ranbaxy partially wins over Lipitor patentIn a partial win for country's biggest drugmaker Ranbaxy Laboratories in the ongoing patent litigation with Pfizer over atorvastatin (Lipit...
- UK court rejects Ranbaxy's appeal against drug patentIn a setback to country's biggest drug maker Ranbaxy Laboratories, the UK Court of Appeal has upheld an earlier ruling by the UK High Court...
Load More
